Suicide risk and antipsychotic side effects in schizophrenia: nested case-control study.
2016 (English)In: Human Psychopharmacology: Clinical and Experimental, ISSN 0885-6222, E-ISSN 1099-1077, Vol. 31, no 4, 341-345 p.Article in journal (Refereed) Published
OBJECTIVE: This study explores suicide risk in schizophrenia in relation to side effects from antipsychotic medication.
METHODS: Among patients with a first clinical discharge diagnosis of schizophrenia or schizoaffective disorder in Stockholm County between 1984 and 2000 (n = 4000), those who died by suicide within 5 years from diagnosis were defined as cases (n = 84; 54% male). For each case, one individually matched control was identified from the same population. Information on antipsychotic side effects, including extrapyramidal symptoms (EPS) and akathisia, as well as prescriptions of anticholinergic medication, was retrieved from clinical records in a blinded fashion. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) of the association between suicide and side effects as well as anticholinergic medication were estimated using conditional logistic regression.
RESULTS: A lower suicide risk was found in patients with a history of EPS (aOR 0.33, 95% CI 0.12-0.94). There was no statistically significant association between akathisia or anticholinergic medication use and the suicide risk.
CONCLUSIONS: A lower suicide risk identified among patients with EPS could potentially reflect higher antipsychotic adherence, exposure to higher dosage, or polypharmacy among these patients.
Place, publisher, year, edition, pages
2016. Vol. 31, no 4, 341-345 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-288908DOI: 10.1002/hup.2536ISI: 000379939200010PubMedID: 27108775OAI: oai:DiVA.org:uu-288908DiVA: diva2:924421
FunderStockholm County CouncilSwedish Research Council, K2007-62X-15078-04-3, K2008-62P-20597-01-3